Quotient Sciences and global investment firm Permira today announced that a company backed by the Permira Funds has signed a definitive agreement to acquire a majority stake in Quotient from companies controlled by GHO Capital and other investors for an undisclosed sum. The investment provides substantial new funding to fuel the next stage of Quotient’s growth. Chief Executive Officer Mark Egerton and the management team will continue to lead Quotient.

Quotient Sciences has brought innovation to the pharmaceutical services sector through its unique Translational Pharmaceutics® platform, which is proven to accelerate development timelines, reduce development costs, and drive improvement in R&D productivity. The business has experienced substantial growth over recent years and generates annual revenues in excess of £100 million.

“We are delighted to partner with Permira to drive Quotient through our continued evolution,” said Mark Egerton, Ph.D., Chief Executive Officer of Quotient Sciences. “The investment by the Permira Funds will support Quotient’s continued growth plans, which include broadening our core services portfolio and expanding our formulation development and manufacturing capabilities to meet the demands of our growing customer base.”

Marcel Lacaze, Principal in the Global Healthcare Group of Permira based in London, added, “Quotient Sciences and its disruptive approach to pharmaceutical drug development have created a truly unique business model. With GHO’s support, the business has developed strongly in recent years and we look forward to partnering with Mark and his team in continuing to grow this exciting company.”

The Partners at GHO Capital have enjoyed working with the Quotient team since 2015. “During this period, the business has achieved a global footprint, replicated its unique Translational Pharmaceutics in the U.S., and validated itself as a commercial drug product manufacturer. Having more than doubled its capacity and made large investments in operational infrastructure, Quotient is well placed to continue its strong performance, and we look forward to seeing their continued success in partnership with Permira.”

Latest Opportunities

Study brief: The effects of a recovery gel on endurance cycling performance in the heat

The popularity of endurance sports like cycling and running has grown significantly over the past…

UKRI unveils new £9 million proof-of-concept fund

The UKRI Proof of Concept funding opportunity aims to support and accelerate the development of…

Peer advice on “demand forecasting strategies”

An established Midlands-based health manufacturer is keen to hear from others about their demand forecasting…

Latest News

Illuminating biology: Advanced imaging and computational techniques transforming medical research at the University of Warwick

Advances in imaging and computational techniques are enabling researchers to discover more than ever before…

From firefighting to future-proofing: Why predictive compliance is key in medical device software

By Medilink Midlands Member Coauthor by Hindsight In today’s fast-paced and highly regulated world of…

IMed Consultancy new whitepaper reveals how to transform gruelling PMS procedures into commercial benefit

IMed Consultancy’s new free whitepaper, “PMS from pain to potential: more than just ticking a…